Technical Analysis for ESPR - Esperion Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | -6.57% | |
Narrow Range Bar | Range Contraction | -6.57% | |
Wide Bands | Range Expansion | -6.57% | |
Oversold Stochastic | Weakness | -6.57% | |
Wide Bands | Range Expansion | -4.78% | |
Oversold Stochastic | Weakness | -4.78% | |
NR7 | Range Contraction | 4.19% | |
Narrow Range Bar | Range Contraction | 4.19% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 20 hours ago |
Fell Below 10 DMA | about 20 hours ago |
10 DMA Support | about 20 hours ago |
Down 5% | about 20 hours ago |
Down 3% | about 20 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Obesity Lipid Cardiology Cholesterol Lipoprotein Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Atherosclerosis Niacin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Obesity Lipid Cardiology Cholesterol Lipoprotein Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Atherosclerosis Niacin
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.4 |
52 Week Low | 0.7 |
Average Volume | 6,535,584 |
200-Day Moving Average | 1.79 |
50-Day Moving Average | 2.42 |
20-Day Moving Average | 2.41 |
10-Day Moving Average | 1.98 |
Average True Range | 0.25 |
RSI (14) | 40.48 |
ADX | 24.69 |
+DI | 17.57 |
-DI | 24.55 |
Chandelier Exit (Long, 3 ATRs) | 2.66 |
Chandelier Exit (Short, 3 ATRs) | 2.45 |
Upper Bollinger Bands | 3.38 |
Lower Bollinger Band | 1.45 |
Percent B (%b) | 0.28 |
BandWidth | 80.02 |
MACD Line | -0.15 |
MACD Signal Line | -0.10 |
MACD Histogram | -0.0428 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.22 | ||||
Resistance 3 (R3) | 2.23 | 2.16 | 2.18 | ||
Resistance 2 (R2) | 2.16 | 2.11 | 2.16 | 2.16 | |
Resistance 1 (R1) | 2.08 | 2.07 | 2.05 | 2.07 | 2.15 |
Pivot Point | 2.01 | 2.01 | 2.00 | 2.01 | 2.01 |
Support 1 (S1) | 1.93 | 1.96 | 1.90 | 1.92 | 1.83 |
Support 2 (S2) | 1.86 | 1.92 | 1.86 | 1.82 | |
Support 3 (S3) | 1.78 | 1.86 | 1.80 | ||
Support 4 (S4) | 1.77 |